Kadmon Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDMN research report →
Companywww.kadmon.com
Kadmon Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer.
- CEO
- Harlan Waksal
- IPO
- 2016
- Employees
- 127
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -14.50
- P/S
- 0.00
- P/B
- 13.61
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.86%
- Op Margin
- -1234.09%
- Net Margin
- -1314.10%
- ROE
- -77.31%
- ROIC
- -73.38%
Growth & Income
- Revenue
- $8.29M · 62.67%
- Net Income
- $-108,913,000 · -77.48%
- EPS
- $-0.66 · -43.48%
- Op Income
- $-102,281,000
- FCF YoY
- -9.17%
Performance & Tape
- 52W High
- $9.50
- 52W Low
- $3.45
- 50D MA
- $8.66
- 200D MA
- $5.35
- Beta
- 1.12
- Avg Volume
- 10.03M
Get TickerSpark's AI analysis on KDMN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 21 | Waksal Harlan | sell | 177,945 |
| Nov 9, 21 | Waksal Harlan | sell | 655,000 |
| Nov 9, 21 | Waksal Harlan | sell | 982,500 |
| Nov 9, 21 | Waksal Harlan | sell | 2,000,000 |
| Nov 9, 21 | Waksal Harlan | sell | 750 |
| Nov 9, 21 | Waksal Harlan | sell | 1,350,000 |
| Nov 9, 21 | Ryan John L | sell | 100,000 |
| Nov 9, 21 | Ryan John L | sell | 250 |
| Nov 9, 21 | Ryan John L | sell | 150,000 |
| Nov 9, 21 | Ryan John L | sell | 50,000 |
Our KDMN Coverage
We haven't published any research on KDMN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KDMN Report →